Potential New Standard of Care for Locally Advanced Cervical Cancer

In this MEDtalk from ESMO 2023, Kristina Lindemann briefs us on the Keynote A18 study, where patients with High-risk locally advanced cervical cancer received pembrolizumab in addition to standard chemo-radiation, vs induction chemotherapy prior to chemo-radiation in the same disease setting. These studies offer the potential to improve the standard of care for patients with locally advanced cervical cancer, also in low and middle-income countries where access to newer treatments like immunotherapy and radiation can be challenging.